Pharmacokinetic Drug-Drug Interaction Study of Rucaparib
Status:
Completed
Trial end date:
2019-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess pharmacokinetic concentrations of multiple probes
alone followed by assessment of the same drug pharmacokinetic concentrations when the patient
has steady-state exposure to rucaparib followed by cycle-by-cycle treatment with rucaparib
continuing until disease progression or other reason for discontinuation.
Phase:
Phase 1
Details
Lead Sponsor:
Clovis Oncology, Inc.
Treatments:
Caffeine Digoxin Midazolam Omeprazole Rucaparib Vitamin K Vitamins Warfarin